These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9231880)

  • 1. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy.
    Schendel DJ; Oberneder R; Falk CS; Jantzer P; Kressenstein S; Maget B; Hofstetter A; Riethmüller G; Nössner E
    J Mol Med (Berl); 1997 Jun; 75(6):400-13. PubMed ID: 9231880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
    Schendel DJ; Gansbacher B
    Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
    Schendel DJ; Falk CS; Nössner E; Maget B; Kressenstein S; Urlinger S; Tampé R; Gansbacher B
    Gene Ther; 2000 Jun; 7(11):950-9. PubMed ID: 10849555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.
    Schendel DJ; Falk CS; Frankenberger B; Noessner E; Schleypen J; Pohla H
    Urologe A; 2004 Sep; 43 Suppl 3():S133-5. PubMed ID: 15179552
    [No Abstract]   [Full Text] [Related]  

  • 6. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cell therapy in renal cell carcinoma].
    Ravaud A
    Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
    Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
    J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved lymphocyte cytotoxicity against murine renal cell carcinoma.
    Salup RR; Sicker DC; Ballou BT; Flack CE; Wolmark N; Hakala TR
    J Urol; 1992 Feb; 147(2):491-5. PubMed ID: 1732630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.
    Shablak A; Hawkins RE; Rothwell DG; Elkord E
    Clin Cancer Res; 2009 Nov; 15(21):6503-10. PubMed ID: 19843660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 13. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW; Fuchs HA
    J Rheumatol; 1994 Apr; 21(4):752-3. PubMed ID: 8035405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 17. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of renal cell carcinoma.
    Pittman K; Selby P
    Crit Rev Oncol Hematol; 1994 Jun; 16(3):181-200. PubMed ID: 7521169
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.
    Slovin SF; Maguire HC; Mastrangelo MJ
    Cancer; 1990 Dec; 66(12):2541-6. PubMed ID: 2123415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
    Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
    Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.